Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
With
AESCA Pharma GmbH
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Prior histologic confirmation of non-small cell lung cancer (NSCLC).
Optional: NSCLC histologic confirmation of metastasis of NSCLC.
Presence of unidimensionally measurable disease in the brain.
No previous or current malignancies at other sites with the exception of adequately treated in situ carcinoma of the cervix or basal and squamous carcinoma of the skin.
Age: \>18 years.
Subjects must not have systemic disease that in the opinion of the investigator is in immediate need of chemotherapy
Any reason making compliance to the protocol improbable.
Clareo Health | Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)
